adavosertib + pegylated liposomal doxorubicin

**Adavosertib + pegylated liposomal doxorubicin** is an experimental combination therapy for cancer, studied primarily in ovarian and other gynecological malignancies. - **Adavosertib** is a small molecule inhibitor of the WEE1 kinase, a cell cycle checkpoint regulator; inhibition drives tumor cells (especially with p53 abnormalities) through the G2/M checkpoint, forcing them to divide in the presence of DNA damage and leading to cell death. - **Pegylated liposomal doxorubicin (PLD)** is a liposome-encapsulated formulation of doxorubicin with a polyethylene glycol (PEG) coating. This delivery extends circulation time and reduces toxicity by selectively accumulating in tumor tissue via the enhanced permeability and retention (EPR) effect. Doxorubicin is an anthracycline cytotoxic agent that intercalates DNA and inhibits topoisomerase II, disrupting DNA replication and repair and producing cell death[2][4][5][7]. - The combination is designed to synergistically increase cancer cell kill by impairing DNA repair (via WEE1 inhibition) and simultaneously damaging DNA (via doxorubicin). - Investigational use is mainly in platinum-resistant or refractory ovarian cancer and other advanced solid tumors[7].

Brand names

Doxil

Other names

adavosertibAZD1775AZD-1775AZD 1775PLDpegylated liposomal doxorubicinliposomal doxorubicin